Proteasome Inhibition Attenuates Infarct Size and Preserves Cardiac Function in a Murine Model of Myocardial Ischemia-Reperfusion Injury

Annals of Thoracic Surgery

Volumn 84, Issue 1, 2007, Pages 120-125

  Stansfield, William E ^a   Moss, Nancy C ^a   Willis, Monte S ^a   Tang, Ruhang ^a   Selzman, Craig H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20S PROTEASOME; I KAPPA B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN BETA LACTONE; MOLECULAR MARKER; PROTEASOME; PROTEASOME INHIBITOR; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME DEGRADATION; GENE EXPRESSION; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART STRESS; HEART VENTRICLE FUNCTION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; TREATMENT OUTCOME;

ACETYLCYSTEINE; ANIMALS; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 34250368734     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2007.02.049     Document Type: Article

References (32)

1. Piper H.M., Meuter K., and Schafer C. Cellular mechanisms of ischemia-reperfusion injury. Ann Thorac Surg 75 (2003) S644-S648
2. Buja L.M. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol 14 (2005) 170-175
3. Kloner R.A., and Rezkalla S.H. Cardiac protection during acute myocardial infarction: where do we stand in 2004?. J Am Coll Cardiol 44 (2004) 276-286
4. Bolli R., Becker L., Gross G., et al. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95 (2004) 125-134
5. Baldwin Jr. A.S. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107 (2001) 3-6
6. Nichols T.C. NF-kappaB and reperfusion injury. Drug News Perspect 17 (2004) 99-104
7. Valen G. Signal transduction through nuclear factor kappa B in ischemia-reperfusion and heart failure. Basic Res Cardiol 99 (2004) 1-7
8. Higgins K.A., Perez J.R., Coleman T.A., et al. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci U S A 90 (1993) 9901-9905
9. Trescher K., Bernecker O., Fellner B., et al. Inflammation and postinfarct remodeling: overexpression of IkappaB prevents ventricular dilation via increasing TIMP levels. Cardiovasc Res 69 (2006) 746-754
10. Di Napoli M., and Papa F. MLN-519. Millennium/PAION. Curr Opin Investig Drugs 4 (2003) 333-341
11. Zollner T.M., Podda M., Pien C., et al. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 109 (2002) 671-679
12. Kane R.C., Farrell A.T., Sridhara R., and Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 12 (2006) 2955-2960
13. Plumier J.C., Robertson H.A., and Currie R.W. Differential accumulation of mRNA for immediate early genes and heat shock genes in heart after ischaemic injury. J Mol Cell Cardiol 28 (1996) 1251-1260
14. Yan S.F., Fujita T., Lu J., et al. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med 6 (2000) 1355-1361
15. Morishita R., Sugimoto T., Aoki M., et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 3 (1997) 894-899
16. Kupatt C., Wichels R., Deiss M., et al. Retroinfusion of NFkappaB decoy oligonucleotide extends cardioprotection achieved by CD18 inhibition in a preclinical study of myocardial ischemia and retroinfusion in pigs. Gene Ther 9 (2002) 518-526
17. Squadrito F., Deodato B., Squadrito G., et al. Gene transfer of IkappaBalpha limits infarct size in a mouse model of myocardial ischemia-reperfusion injury. Lab Invest 83 (2003) 1097-1104
18. Li C., Ha T., Liu L., Browder W., and Kao R.L. Adenosine prevents activation of transcription factor NF-kappa B and enhances activator protein-1 binding activity in ischemic rat heart. Surgery 127 (2000) 161-169
19. Zingarelli B., Hake P.W., Denenberg A., and Wong H.R. Sesquiterpene lactone parthenolide, an inhibitor of IkappaB kinase complex and nuclear factor-kappaB, exerts beneficial effects in myocardial reperfusion injury. Shock 17 (2002) 127-134
20. Thiemermann C. Inhibition of the activation of nuclear factor kappa B to reduce myocardial reperfusion injury and infarct size. Cardiovasc Res 63 (2004) 8-10
21. Kis A., Yellon D.M., and Baxter G.F. Role of nuclear factor-kappa B activation in acute ischaemia-reperfusion injury in myocardium. Br J Pharmacol 138 (2003) 894-900
22. Yoo C.G., Lee S., Lee C.T., Kim Y.W., Han S.K., and Shim Y.S. Effect of acetylsalicylic acid on endogenous I kappa B kinase activity in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 280 (2001) L3-L9
23. Holschermann H., Schuster D., Parviz B., Haberbosch W., Tillmanns H., and Muth H. Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis 185 (2006) 240-245
24. Ross A.M., Gibbons R.J., Stone G.W., Kloner R.A., and Alexander R.W. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 45 (2005) 1775-1780
25. Berti R., Williams A.J., Velarde L.C., et al. Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat. Neurotox Res 5 (2003) 505-514
26. Williams A.J., Berti R., Dave J.R., Elliot P.J., Adams J., and Tortella F.C. Delayed treatment of ischemia/reperfusion brain injury: extended therapeutic window with the proteosome inhibitor MLN519. Stroke 35 (2004) 1186-1191
27. Williams A.J., Dave J.R., and Tortella F.C. Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration. Neurochem Int 49 (2006) 106-112
28. Gao Y., Lecker S., Post M.J., et al. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest 106 (2000) 439-448
29. Bao J., Sato K., Li M., et al. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am J Physiol Heart Circ Physiol 281 (2001) H2612-H2618
30. Hall G., Hasday J.D., and Rogers T.B. Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 41 (2006) 580-591
31. Pye J., Ardeshirpour F., McCain A., et al. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 284 (2003) H919-H926
32. Williams A.J., Myers T.M., Cohn S.I., Sharrow K.M., Lu X.C., and Tortella F.C. Recovery from ischemic brain injury in the rat following a 10 h delayed injection with MLN519. Pharmacol Biochem Behav 81 (2005) 182-189